HeartWare International Inc

HeartWare International — Technical Presentation (April 2008)

16 slides from HeartWare International's technical presentation, Apr 14, 2008

  1. Slide 1: Experience with the Novel HeartWare LVAS with Hydromagnetically Levitated Rotor in a Multi-institutional Trial

    Experience with the Novel HeartWare(r) LVAS with Hydromagnetically Levitated Rotor in a Multi-institutional Trial G.M. Wieselthaler, M. Strueber, G.A. O^Driscoll, P. Jansz and A. Khaghani A Report On The First 23 Human Implants

  2. Slide 2: HeartWare Design Features

    HeartWare Design Features One moving part, no mechanical bearings and passive impeller system Small centrifugal pump, 50 cc, 140 gms, 2" outside diameter Integrated inflow cannula 10 mm outflow graft with strain relief Dual motor stators for pump power redundancy Thin, flexible driveline (4.2 mm)

  3. Slide 3: Surgical Implant in the Pericardial Space

    Surgical Implant in the Pericardial Space HeartWare(r) pump is implanted in the pericardial space Integrated inflow cannula and novel sewing ring designed to expedite the implant procedure

  4. Slide 4: International HeartWare BTT Trial Centers

    International HeartWare BTT Trial Centers # Patients Vienna General Hospital, Austria 7 Georg Wieselthaler, Henrich Schima Royal Perth Hospital, Australia 4 Gerry O'Driscoll, Rob Larbalestier, Lawrence Dembo Hannover Medical Center, Germany 6 Martin Strueber, Christian Kuehn, Anna Myer Harefield Hos

  5. Slide 5: Patient Demographics

    Patient Demographics Patients: 23 Gender: 20 Males and 3 Females Age: 26 to 68 years (mean 47.9 yrs) BSA: 1.51 to 2.56 m2 (mean 1.98 m2) Weight: 47.8 to 138 kg (mean 83.7 kg) Idiopathic Ischemic Viral 14 7 2 Idiopathic 14 Ischemic 7 Viral 2 Etiology of Disease

  6. Slide 6: Preoperative Hemodynamics

    Preoperative Hemodynamics Parameter HeartWare HM II* Cardiac Index (L/min/m2) 1.9 +- 0.5 2.0 +- 0.6 LVEF (%) 20.6 +- 7.4 16.3 +- 5.7 BP Systolic (mmHg) 105 +- 15.8 95.8 +- 14.6 BP Diastolic (mmHg) 67 +- 8.9 61.7 +- 11.3 Mean BP (mmHg) 79 +- 10.2 73 PCWP (mmHg) 23.1 +- 7 26.1 +- 7.9 PA Systolic (mmHg

  7. Slide 7: Outcomes at 180 Days for First Implants

    Outcomes at 180 Days for First 23 Implants At 180 days: Survival - 91% Transplant- 9% Recovery - 0% Death - 9%

  8. Slide 8: Summary of Overall Outcomes of First Implants

    Summary of Overall Outcomes of First 23 Implants N = 23 N = 23 Ongoing or Transplanted 21 - Transplanted (earliest POD 157) 2 - Ongoing >180 days 17 <180 days 2 Expired 2 (13, 84 days) - Sepsis 2 At 180 days

  9. Slide 9: Explanted Pump From First Implant

    Explanted Pump From First Implant Pathology pictures after 427 days Pump housing Impeller Courtesy of Texas A&M University by Dr. Fred Clubb, D.V.M., Ph.D., DACLAM, Clinical Professor

  10. Slide 10: Hemodynamic Changes After LVAD Implant

    Hemodynamic Changes After LVAD Implant Parameter Pre POD 1 POD 2 MAP (mmHg) 79 + 10.2 81 + 15.4 75 + 12.2 PAP (mmHg) 37 + 12.2 27 + 7.3 25 + 7.6 PCWP (mmHg) 23 + 7.2 12.2 + 3.1 11.6 + 2.6 RAP (mmHg) 13 + 5.7 12.6 + 2.1 11.4 + 4.2 CI/Flow Index L/min/m2 1.9 + 0.5 3.2 + 0.48 2.9 + 0.45

  11. Slide 11: Key Laboratory Parameters

    Key Laboratory Parameters Week 1 Week 2 Week 4 Week 8 Week 12 Week 26 Creatinine 1.3 1.17 1.18 1.08 1.1 1.12 Bilirubin 2.65 4 1.22 0.86 0.82 0.88 Plasma Free Hgb 6.2 3.5 3.2 5.3 2.6 3.4 mg/dL

  12. Slide 12: Adverse Events In First Implants

    Adverse Events In First 23 Implants Complication Patients Events Event Rate N N per pt yr Infections (exit site) 3 3 0.28 Bleeding (requiring re-operation) 3 4 0.37 Respiratory Dysfunction 4 4 0.37 Renal Dysfunction 3 3 0.28 Right Heart Failure 1 1 0.09 Device Replaced** 2 2 0.19 **Manufacturing cha

  13. Slide 13: Neurological Adverse Events In First Implants

    Neurological Adverse Events In First 23 Implants Complication Patients Events Event Rate N N per pt yr TIA (POD 15) 1 1 0.09 Stroke (POD 8, 12) -Ischemic* 2 2 0.19 -Hemorrhagic 0 0 0.00 Recovered 3 Expired 0 * - one patient with HIT At 180 days

  14. Slide 14: Conclusions From First Human Implants (180 days)

    Conclusions From First 23 Human Implants (180 days) Successful Pericardial Placement of the HeartWare(r) LVAD 91% survival at 180-days (trial endpoint met) Comparable Adverse Event profile Able to support a broad range of patient needs Mean flow of 6 liters per minute

  15. Slide 15: Post-180 Days Summary of Overall Outcomes of First Implants

    Post-180 Days Summary of Overall Outcomes of First 23 Implants N = 23 (mean duration of support 272 days) N = 23 (mean duration of support 272 days) Ongoing or Transplanted 19 - Transplanted (earliest POD 157) 6 - Ongoing >180 days 11 <180 days 2 Longest Duration of Support 466 days Recovered / Expl

  16. Slide 16: Conclusions From First Human Implants (data through Feb 2, 2008)

    Conclusions From First 23 Human Implants (data through Feb 22, 2008) Successful Pericardial Placement of the HeartWare(r) LVAD No pump pocket No intrathoracic infections No cannula obstructions 91% survival at 180-days Comparable Adverse Event profile Able to support a broad range of patient needs M

HeartWare — Technical Presentation (April 2008) on 6ix